IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with ... - BioSpace
IDMC recommended continuation of IO Biotech's Phase 3 trial of IO102-IO103 without modifications after a safety and efficacy interim analysis. No new safety signals were observed, and the primary endpoint of progression-free survival is projected to be reached in the first half of 2025.
Related Clinical Trials
Reference News
IDMC recommended continuation of IO Biotech's Phase 3 trial of IO102-IO103 without modifications after a safety and efficacy interim analysis. No new safety signals were observed, and the primary endpoint of progression-free survival is projected to be reached in the first half of 2025.
IO Biotech's Phase III trial of IO102-IO103 vaccine with pembrolizumab for advanced melanoma received IDMC recommendation to continue after interim analysis. The open-label, randomized trial compares the combination to pembrolizumab alone, enrolling 407 patients across multiple countries. No new safety signals were observed, and the primary endpoint of progression-free survival is expected in H1 2025.